Sergei Tjulandin
Russian Academy
174 Papers
908 Citations
Sergei Tjulandin is an academic researcher from Russian Academy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 42, co-authored 150 publications. Previous affiliations of Sergei Tjulandin include Katholieke Universiteit Leuven.
Chat about Author
Papers
385P The prognostic value of circulating in blood tumor DNA after surgery in I-III stages colorectal cancer
E. Polyanskaya,Mikhail Fedyanin,Borisova Uliana,Andrey Kechin,Elena Moroz,E. A. Khrapov,I. Oskorobin,Serebryakova Darya,Vechaslav Aliev,Alexey Tryakin,Maxim L. Filipenko,Sergei Tjulandin +11 more
TL;DR: In this article , the prognostic role of circulating tumor DNA (ctDNA) after surgery was studied in patients with stage I-III colorectal cancer and stage II with unfavorable prognosis factors.
The most important results of clinical trials for breast cancer systemic therapy in 2021
TL;DR: The most significant results of recent studies of various issues of systemic therapy for both early and metastatic breast cancer are discussed, with a focus on standard and new therapy regimens.
O-0011frequency of s492r mutations in the epidermal growth factor receptor: analysis of plasma dna from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy
Kathryn J. Newhall,Timothy J. Price,Monika Peeters,Tark Kim,Juan Li,Stefano Cascinu,Paul Ruff,Attili Satya Suresh,Anne L. Thomas,Sergei Tjulandin,Selam Ogbagabriel,Michael Boedigheimer,S. Sexson,Kathy Zhang,Swaminathan Murugappan,Roger Sidhu +15 more
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Stephen R. D. Johnston,Roberto Hegg,Seock-Ah Im,In Hae Park,Olga Burdaeva,G. Kurteva,Michael F. Press,Sergei Tjulandin,Hiroji Iwata,Sergio Daniel Simon,Sarah Kenny,Severine Sarp,Miguel Izquierdo,L. S. Williams,William J. Gradishar +14 more
TL;DR: The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy.
Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study.
Ilya Tsimafeyeu,Evgeny N. Imyanitov,Larisa E. Zavalishina,Grigory A. Raskin,Patrisia Povilaitite,Nikita Savelov,Ekaterina Kharitonova,Alexey Rumyantsev,Inna Pugach,Yulia I. Andreeva,Alexey Petrov,G A Frank,Sergei Tjulandin +12 more
TL;DR: A low correlation was observed between the PCR test and each of the three IHC assays; however, if a patient tested low/negative by PCR, then they were likely to test negative by any single IHC test with a high probability, and this method may have some potential for the identification of PDL1-negative tumors.